Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 11, 2000

View Archived Issues

Tibolone plus long-term GnRH agonist evaluated in uterine leiomyoma therapy

Thalidomide for therapy of refractory multiple myeloma

Results of interim review support continuation of phase II study evaluating P45

Schering to buy Mitsui Pharmaceuticals

IL-15 potentiates the antiviral response of natural killer cells in vitro

Pharmacia & Upjohn seeks approval for combination glaucoma therapy

FDA grants priority review status to Wyeth-Ayerst's therapy for relapsed adult AML

Cangene revamps Leucotropin clinical trial program

Abbott and NeuroSearch enter nervous system disorder collaboration

Unigene files IND for nasal calcitonin

Organon signs exclusive agreement with CIMA

ADNF III/ADNP antisense oligonucleotides available for licensing from NIH

Neurocrine Biosciences licenses antidiabetic compound to Taisho

New combination therapy for depression with reduced side effects

Human Genome Sciences discloses novel growth-regulatory protein, its production and use

Merck initiates human testing of prophylactic anti-HIV naked DNA vaccine

Millennium reports discovery of apoptosis-linked proteins

16-HETE analogues useful for treating conditions associated with neutrophil adhesion/aggregation

Synthesis and biological activity of new radicicol derivatives presented by Kyowa Hakko

Compounds for osteoporosis in development at Japanese lab

Japanese patent covers new selectin inhibitors useful for inflammatory conditions

Pharmacia & Upjohn and Searle to copromote Detrol

Millennium licenses chronic asthma treatment to Taisho

Once-daily antidiabetic drug from Andrx steadily advances towards market launch

Priority review granted to antihypertensive drug Vanlev

More disappointing clinical results reported for Interneuron's stroke drug

Aventis acquires Hoechst-Ariad Genomics Center

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...